Avey Leaves 23andMe to Start Alzheimer's Research Foundation Using DTC Genomics Firm's Platform

The new Alzheimer's disease research foundation to be launched by Linda Avey will use 23andMe's research platform and its database of genetic risk association information to investigate the causes and discover new treatments for the disease.

Full-text access for premium subscribers only. Existing premium subscribers login here.
New to GenomeWeb? Register here quickly.